Historical salary details - Mr. Kurt von Emster, C.F.A., Independent Director, Jasper Therapeutics Inc
Mr. Kurt von Emster, C.F.A. is the Independent Director of Jasper Therapeutics Inc.
Mr. Kurt Von Emster, C.F.A.
Independent Director
-
Gross Remuneration
-
Current Company
Jasper Therapeutics Inc
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2024 | Jasper Therapeutics Inc | Independent Director | - | - |
| 2023 | Jasper Therapeutics Inc | - | 128.2 K | -54.9 % |
| 2023 | Cymabay Therapeutics Inc | Independent Director | - | - |
| 2022 | Jasper Therapeutics Inc - Warrants (24/09/2026) | Independent Director | 284.2 K | - |
| 2022 | Jasper Therapeutics Inc | Independent Director | 284.2 K | 1645.3 % |
| 2022 | Cymabay Therapeutics Inc | Independent Director | 193.3 K | -0.7 % |
| 2022 | Vaxcyte Inc | Independent Director | 23.1 K | -92.0 % |
| 2022 | Vera Therapeutics Inc - Ordinary Shares - Class A | Chairman of the Board | - | - |
| 2022 | Vaxcyte Inc | Interim Chairman of the Board | - | - |
| 2021 | Vaxcyte Inc | Interim Chairman of the Board | 287.9 K | -41.1 % |
| 2021 | Cymabay Therapeutics Inc | Independent Director | 194.7 K | -6.2 % |
| 2021 | Vera Therapeutics Inc - Ordinary Shares - Class A | Chairman of the Board | 114.6 K | - |
| 2021 | Jasper Therapeutics Inc | Independent Director | 16.3 K | - |
| 2020 | Vaxcyte Inc | Interim Chairman of the Board | 488.7 K | - |
| 2020 | Cymabay Therapeutics Inc | Independent Director | 207.6 K | -0.4 % |
| 2020 | Vera Therapeutics Inc - Ordinary Shares - Class A | Independent Director | - | - |
| 2020 | Jasper Therapeutics Inc | Independent Director | - | - |
| 2019 | Cymabay Therapeutics Inc | Independent Director | 208.5 K | 18.9 % |
| 2019 | CRISPR Therapeutics AG | - | 22.4 K | -96.5 % |
| 2019 | CRISPR Therapeutics AG | Independent Director | - | - |
| 2019 | Vaxcyte Inc | Independent Director | - | - |
| 2018 | CRISPR Therapeutics AG | Independent Director | 646.8 K | 254.5 % |
| 2018 | Cymabay Therapeutics Inc | Independent Director | 175.3 K | 18.9 % |
| 2017 | CRISPR Therapeutics AG | Independent Director | 182.5 K | -40.3 % |
| 2017 | Cymabay Therapeutics Inc | Independent Director | 147.4 K | 133.1 % |
| 2016 | CRISPR Therapeutics AG | Independent Director | 305.8 K | - |
| 2016 | Cymabay Therapeutics Inc | Independent Director | 63.2 K | -49.0 % |
| 2015 | Cymabay Therapeutics Inc | Independent Director | 123.8 K | 74.0 % |
| 2015 | CRISPR Therapeutics AG | Independent Director | - | - |
| 2014 | Cymabay Therapeutics Inc | Independent Director | 71.2 K | 47.4 % |
| 2014 | Aurinia Pharmaceuticals Inc | Director | 61.9 K | - |
| 2013 | Cymabay Therapeutics Inc | Independent Director | 48.3 K | 1487.1 % |
| 2012 | Cymabay Therapeutics Inc | Independent Director | 3.0 K | - |